BioCentury
ARTICLE | Clinical News

Telik starts TLK286 trial in ovarian cancer

May 29, 2001 7:00 AM UTC

TELK began open-label U.S. Phase II testing of TLK286 in patients with platinum-resistant advanced epithelial ovarian cancer. Patients will receive TLK286 every 3 weeks, and the trial will measure obj...